PKP2-Arrhythmogenic Cardiomyopathy – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
- Published Date : September 2, 2026
- Updated On : November 4, 2026
- Pages : 53
PKP2-Arrhythmogenic Cardiomyopathy Emerging Therapy and TPP Insights
Thelansis’s “PKP2-Arrhythmogenic Cardiomyopathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
PKP2-Arrhythmogenic Cardiomyopathy Overview
PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) is an inherited cardiac disorder caused by pathogenic variants in PKP2, encoding desmosomal protein plakophilin-2. Usually autosomal dominant with variable penetrance, it weakens cell adhesion and promotes myocardial injury and fibrofatty replacement, often right-predominant. Palpitations, syncope and ventricular arrhythmias may occur; heart failure or sudden cardiac death can develop. Assessment combines ECG, rhythm monitoring, cardiac imaging and genetic testing, with family screening. Management includes avoiding high-intensity endurance exercise, beta-blockers or selected antiarrhythmics, catheter ablation for recurrent ventricular tachycardia, and an implantable cardioverter-defibrillator for patients at appropriate risk. No gene therapy or disease-modifying treatment is approved. AAV gene-replacement candidates LX2020, TN-401 and RP-A601 are in early clinical studies; their effect on disease progression remains unproven.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
PKP2-Arrhythmogenic Cardiomyopathy Emerging Therapy and TPP Insights
Thelansis’s “PKP2-Arrhythmogenic Cardiomyopathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
PKP2-Arrhythmogenic Cardiomyopathy Overview
PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) is an inherited cardiac disorder caused by pathogenic variants in PKP2, encoding desmosomal protein plakophilin-2. Usually autosomal dominant with variable penetrance, it weakens cell adhesion and promotes myocardial injury and fibrofatty replacement, often right-predominant. Palpitations, syncope and ventricular arrhythmias may occur; heart failure or sudden cardiac death can develop. Assessment combines ECG, rhythm monitoring, cardiac imaging and genetic testing, with family screening. Management includes avoiding high-intensity endurance exercise, beta-blockers or selected antiarrhythmics, catheter ablation for recurrent ventricular tachycardia, and an implantable cardioverter-defibrillator for patients at appropriate risk. No gene therapy or disease-modifying treatment is approved. AAV gene-replacement candidates LX2020, TN-401 and RP-A601 are in early clinical studies; their effect on disease progression remains unproven.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
